Financial Analysis: Miragen Therapeutics (MGEN) versus Its Peers

Miragen Therapeutics (NASDAQ: MGEN) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare Miragen Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

19.0% of Miragen Therapeutics shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 16.8% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Miragen Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Miragen Therapeutics -662.30% -63.57% -51.14%
Miragen Therapeutics Competitors -110.24% -188.04% -38.52%

Analyst Recommendations

This is a summary of current recommendations and price targets for Miragen Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics 0 0 9 0 3.00
Miragen Therapeutics Competitors 107 449 528 17 2.41

Miragen Therapeutics presently has a consensus target price of $17.19, suggesting a potential upside of 164.42%. As a group, “Medical laboratories” companies have a potential upside of 17.44%. Given Miragen Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Miragen Therapeutics is more favorable than its peers.

Valuation and Earnings

This table compares Miragen Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Miragen Therapeutics $4.00 million -$26.51 million -4.71
Miragen Therapeutics Competitors $1.13 billion $77.59 million 202.61

Miragen Therapeutics’ peers have higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Miragen Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Miragen Therapeutics’ peers have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.

Summary

Miragen Therapeutics peers beat Miragen Therapeutics on 7 of the 13 factors compared.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ExclusiveCoin  Price Hits $1.22 on Exchanges
ExclusiveCoin Price Hits $1.22 on Exchanges
Comparing Marriott International  and Its Competitors
Comparing Marriott International and Its Competitors
Head to Head Comparison: Synaptics  & LightPath Technologies
Head to Head Comparison: Synaptics & LightPath Technologies
eBitcoin Price Reaches $0.16
eBitcoin Price Reaches $0.16
Social Price Reaches $0.48
Social Price Reaches $0.48
Momo Inc  Given Consensus Rating of “Buy” by Analysts
Momo Inc Given Consensus Rating of “Buy” by Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.